Retatrolide is a novel triple agonist targeting GLP-1, GIP, and glucagon receptors. Clinical trials have shown significant weight loss effects. Here is a brief summary of its efficacy based on available data:
Key findings from clinical trials:
● Phase 2 trial results: Participants taking the highest dose (12 mg) of retatrolide lost approximately 24% of their body weight over 48 weeks (approximately 11 months).
○ For a person weighing 100 kg, this translates to an average weight loss of approximately 2% per month, or approximately 0.5 kg (approximately 1.1 lbs) per week.
○ Weight loss is typically non-linear, with rapid initial results (similar to other weight loss drugs), followed by a plateau.
Comparison with other drugs:
● Smegglutide (Wegovy): Approximately 15% weight loss over 68 weeks.
● Tilaptratide (Zepbound): Approximately 20-22% weight loss over 72 weeks.
● Retatrutide achieved a 24% improvement rate within 48 weeks, indicating faster and more significant efficacy, likely due to its triple mechanism of action.
Important Considerations:
1. Dose-dependent response: Higher doses result in greater weight loss.
2. Individual variability: Results depend on factors such as baseline weight, diet, exercise, and metabolism.
3. Safety: As with other GLP-1 inhibitors, gastrointestinal side effects (nausea, diarrhea) are common. Long-term safety data are still under investigation.
Conclusion:
Retatrutide shows good potential for rapid and significant weight loss, with clinical trial participants experiencing approximately 24% weight loss in less than a year. However, individual efficacy varies, therefore its use should be under the guidance of a healthcare professional. Always consult your doctor before taking any weight-loss medication.
Whatsapp: ＋85246360786
sararaws128@gmail.com